Rapid Multiplexed Immunoassay for Simultaneous Serodiagnosis of HIV-1 and Coinfections
-
- Michael J. Lochhead
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Kathryn Todorof
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Marie Delaney
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Jeffrey T. Ives
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Charles Greef
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Kevin Moll
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Keagan Rowley
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Kurt Vogel
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Chris Myatt
- MBio Diagnostics, Inc., Boulder, Colorado 80301
-
- Xing-Quan Zhang
- Division of Infectious Diseases, University of California, San Diego, California 92093
-
- Cathy Logan
- Division of Infectious Diseases, University of California, San Diego, California 92093
-
- Constance Benson
- Division of Infectious Diseases, University of California, San Diego, California 92093
-
- Sharon Reed
- Division of Infectious Diseases, University of California, San Diego, California 92093
-
- Robert T. Schooley
- Division of Infectious Diseases, University of California, San Diego, California 92093
書誌事項
- 公開日
- 2011-10
- 権利情報
-
- https://journals.asm.org/non-commercial-tdm-license
- DOI
-
- 10.1128/jcm.00970-11
- 公開者
- American Society for Microbiology
この論文をさがす
説明
<jats:title>ABSTRACT</jats:title><jats:p>Diagnosis of opportunistic infections in HIV-infected individuals remains a major public health challenge, particularly in resource-limited settings. Here, we describe a rapid diagnostic system that delivers a panel of serologic immunoassay results using a single drop of blood, serum, or plasma. The system consists of disposable cartridges and a simple reader instrument, based on an innovative implementation of planar waveguide imaging technology. The cartridge incorporates a microarray of recombinant antigens and antibody controls in a fluidic channel, providing multiple parallel fluorescence immunoassay results for a single sample. This study demonstrates system performance by delivering antibody (Ab) reactivity results simultaneously for multiple antigens of HIV-1,<jats:named-content content-type="genus-species">Treponema pallidum</jats:named-content>(syphilis), and hepatitis C virus (HCV) in a collection of clinical serum, plasma, and whole-blood samples. By plotting antibody reactivity (fluorescence intensity) for known positive and negative samples, empirical reactivity cutoff values were defined. The HIV-1 assay shows 100% agreement with known seroreactivity for a collection of 82 HIV Ab-positive and 142 HIV Ab-negative samples, including multiple samples with HCV and syphilis coinfection. The treponema-specific syphilis assay correctly identifies 67 of 68<jats:named-content content-type="genus-species">T. pallidum</jats:named-content>Ab-positive and 100 of 102<jats:named-content content-type="genus-species">T. pallidum</jats:named-content>Ab-negative samples, and the HCV assay correctly identifies 59 of 60 HCV Ab-positive and 120 of 121 HCV Ab-negative samples. Multiplexed assay performance for whole-blood samples is also demonstrated. The ability to diagnose HIV and opportunistic infections simultaneously at the point of care should lead to more effective therapy decisions and improved linkage to care.</jats:p>
収録刊行物
-
- Journal of Clinical Microbiology
-
Journal of Clinical Microbiology 49 (10), 3584-3590, 2011-10
American Society for Microbiology